对中国高级软组织肉瘤的第一线治疗的成本效益分析
Jianping Zhang1, Yifang Liang2, Xin Guan2,3
1Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal of medical economics
|July 25, 2025
概括
传统化疗是中国先进软组织肉瘤 (STSs) 的最具成本效益的第一线治疗方法. 如果使用脂质体 doxorubicin,可能更喜欢安洛丁尼布,突出治疗的敏感性.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 先进的软组织肉瘤 (STSs) 存在重大治疗挑战.
- 评估一线治疗的成本效益对于医疗保健系统的资源配置至关重要.
研究的目的:
- 评估anlotinib,pazopanib,regorafenib和常规化疗作为中国高级STS的第一线治疗方法的成本效益.
主要方法:
- 一个分区的生存模型模拟了生命周期的成本和质量调整后生命年 (QALYs).
- 治疗疗效基于网络元分析 (NMA).
- 成本和医疗公用事业分别来自中国数据库和SABINE研究.
主要成果:
- 传统化疗产生了0.76个QALY,价格为76,052元人民币.
- 雷戈拉费尼布的增量成本效益比率 (ICER) 超过了中国的支付意愿 (WTP) 门.
- 敏感性分析证实了基准案例的发现.
结论:
- 常规化疗 (多克索鲁比注射) 是中国先进的STS中最具成本效益的第一线选择.
- 如果使用脂质体 doxorubicin,安洛提尼布成为首选的经济有效的选择,这表明对化疗配方的敏感性.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456


